Merck Healthcare today announced a license agreement with Abbisko Therapeutics Co. Ltd, Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign…
Roche announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat…
Vincent, what is Servier’s approach to the topic of decarbonization, and more specifically the “energy transition”? The Group’s 2030 vision is very clear: we want to have a significant social impact for patients and for a sustainable world. As a…
AbbVie and ImmunoGen today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie’s commercial and clinical…
BD (Becton, Dickinson and Company), a leading global medical technology company, launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.…
Below are some of the key initiatives undertaken by the Task Force so far: Along with other members, Roche is in advanced discussions with energy providers in China to scale renewable power across their supply chains that will help to…
Hurdle, a pioneer in diagnostic testing, and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies’ shared ambition to…
Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. “We are very excited to collaborate with the research team at IBM,…
Roche today announced the launch of Elecsys® HBeAg quant, an immunoassay that is able to determine both the presence and quantity (qualitative and quantitative) of the hepatitis B e antigen (HBeAg) in human serum and plasma. This launch means that,…
Novo Nordisk announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. The investment…